November 2 (SeeNews) - Bulgarian pharmaceuticals trader Sopharma Trading [BUL:SFT] reported a non-consolidated net profit of 21.9 million levs ($11.09 million/11.2 million euro) for the first nine months of 2022, up from 18.3 million levs a year earlier.
The company’s revenue rose to 803.4 million lev in the January-September period from 720.3 million lev in the same period of 2021, Sopharma Trading said in an interim financial statement on Monday.
At the same time, operating expenses widened to 776.4 million levs from 696.7 million levs, driven by higher cost of goods sold.
In the third quarter alone, Sopharma Trading sales increased by 11.29% on the year to 272.3 million levs. Sales of products in the company's pharmacy network accounted for 49.08% of total sales, while sales to hospitals contributed 28.75%.
The company said it controlled a share of 21.73% of the Bulgarian pharmaceuticals market in the third quarter, including a 19.08% share on the pharmacy segment, and 29.29% on the hospital segment.
Sopharma Trading is a unit of Bulgarian pharmaceuticals producer Sopharma [BUL:SFA], which held a stake of 86.05% in the company at the end of September.
As at 1410 CET on Wednesday, Sopharma Trading's shares traded flat at 5.52 levs on the Sofia bourse.
(1 euro = 1.95583 levs)